An update on therapies for the treatment of diabetes-induced osteoporosis

Sahar Mohsin, May M.Y.H. Baniyas, Reem S.M.H. AlDarmaki, K. Tekes, H. Kalász, Ernest A. Adeghate

Research output: Contribution to journalArticle

Abstract

Introduction: Currently, 424 million people aged between 20 and 79 years worldwide are diabetic. More than 25% of adults aged over 65 years in North America have Type 2 diabetes mellitus (DM). Diabetes-induced osteoporosis (DM-OS) is caused by chronic hyperglycemia, advanced glycated end products and oxidative stress. The increase in the prevalence of DM-OS has prompted researchers to develop new biological therapies for the management of DM-OS. Areas covered: This review covered the current and novel biological agents used in the management of DM-OS. Data were retrieved from PubMed, Scopus, American Diabetes Association and International Osteoporosis Foundation websites, and ClinicalTrials.gov. The keywords for the search included: DM, osteoporosis, and management. Expert opinion: Several biological molecules have been examined in order to find efficient drugs for the treatment of DM-OS. These biological agents include anti-osteoporosis drugs: net anabolics (parathyroid hormone/analogs, androgens, calcilytics, anti-sclerostin antibody), net anti-resorptive osteoporosis drugs (calcitonin, estrogen, selective estrogen receptor modulators, bisphosphonates, RANKL antibody) and anti-diabetic drugs (alpha glucosidase inhibitors, sulfonylureas, biguanides, meglitinides, thiazolidinediones, GLP-1 receptor agonists, dipeptidylpeptidase-4 inhibitors, sodium glucose co-transporter-2 inhibitors, insulin). Biological medications that effectively decrease hyperglycemia and, at the same time, maintain bone health would be an ideal drug/drug combination for the treatment of DM-OS.

Original languageEnglish
JournalExpert Opinion on Biological Therapy
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Medical problems
Osteoporosis
Diabetes Mellitus
Pharmaceutical Preparations
Biological Factors
Hyperglycemia
Therapeutics
Sodium-Glucose Transporter 2
Anti-Idiotypic Antibodies
Testosterone Congeners
Biguanides
Symporters
Selective Estrogen Receptor Modulators
Thiazolidinediones
Biological Therapy
Diphosphonates
Expert Testimony
Calcitonin
Drug Combinations
North America

Keywords

  • anti-diabetic drugs
  • anti-osteoporosis drugs
  • bone
  • bone mineral density
  • Diabetes-induced osteoporosis
  • hormones

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

An update on therapies for the treatment of diabetes-induced osteoporosis. / Mohsin, Sahar; Baniyas, May M.Y.H.; AlDarmaki, Reem S.M.H.; Tekes, K.; Kalász, H.; Adeghate, Ernest A.

In: Expert Opinion on Biological Therapy, 01.01.2019.

Research output: Contribution to journalArticle

Mohsin, Sahar ; Baniyas, May M.Y.H. ; AlDarmaki, Reem S.M.H. ; Tekes, K. ; Kalász, H. ; Adeghate, Ernest A. / An update on therapies for the treatment of diabetes-induced osteoporosis. In: Expert Opinion on Biological Therapy. 2019.
@article{b210d3970f33463fa9fb3455b2d4a470,
title = "An update on therapies for the treatment of diabetes-induced osteoporosis",
abstract = "Introduction: Currently, 424 million people aged between 20 and 79 years worldwide are diabetic. More than 25{\%} of adults aged over 65 years in North America have Type 2 diabetes mellitus (DM). Diabetes-induced osteoporosis (DM-OS) is caused by chronic hyperglycemia, advanced glycated end products and oxidative stress. The increase in the prevalence of DM-OS has prompted researchers to develop new biological therapies for the management of DM-OS. Areas covered: This review covered the current and novel biological agents used in the management of DM-OS. Data were retrieved from PubMed, Scopus, American Diabetes Association and International Osteoporosis Foundation websites, and ClinicalTrials.gov. The keywords for the search included: DM, osteoporosis, and management. Expert opinion: Several biological molecules have been examined in order to find efficient drugs for the treatment of DM-OS. These biological agents include anti-osteoporosis drugs: net anabolics (parathyroid hormone/analogs, androgens, calcilytics, anti-sclerostin antibody), net anti-resorptive osteoporosis drugs (calcitonin, estrogen, selective estrogen receptor modulators, bisphosphonates, RANKL antibody) and anti-diabetic drugs (alpha glucosidase inhibitors, sulfonylureas, biguanides, meglitinides, thiazolidinediones, GLP-1 receptor agonists, dipeptidylpeptidase-4 inhibitors, sodium glucose co-transporter-2 inhibitors, insulin). Biological medications that effectively decrease hyperglycemia and, at the same time, maintain bone health would be an ideal drug/drug combination for the treatment of DM-OS.",
keywords = "anti-diabetic drugs, anti-osteoporosis drugs, bone, bone mineral density, Diabetes-induced osteoporosis, hormones",
author = "Sahar Mohsin and Baniyas, {May M.Y.H.} and AlDarmaki, {Reem S.M.H.} and K. Tekes and H. Kal{\'a}sz and Adeghate, {Ernest A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/14712598.2019.1618266",
language = "English",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - An update on therapies for the treatment of diabetes-induced osteoporosis

AU - Mohsin, Sahar

AU - Baniyas, May M.Y.H.

AU - AlDarmaki, Reem S.M.H.

AU - Tekes, K.

AU - Kalász, H.

AU - Adeghate, Ernest A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Currently, 424 million people aged between 20 and 79 years worldwide are diabetic. More than 25% of adults aged over 65 years in North America have Type 2 diabetes mellitus (DM). Diabetes-induced osteoporosis (DM-OS) is caused by chronic hyperglycemia, advanced glycated end products and oxidative stress. The increase in the prevalence of DM-OS has prompted researchers to develop new biological therapies for the management of DM-OS. Areas covered: This review covered the current and novel biological agents used in the management of DM-OS. Data were retrieved from PubMed, Scopus, American Diabetes Association and International Osteoporosis Foundation websites, and ClinicalTrials.gov. The keywords for the search included: DM, osteoporosis, and management. Expert opinion: Several biological molecules have been examined in order to find efficient drugs for the treatment of DM-OS. These biological agents include anti-osteoporosis drugs: net anabolics (parathyroid hormone/analogs, androgens, calcilytics, anti-sclerostin antibody), net anti-resorptive osteoporosis drugs (calcitonin, estrogen, selective estrogen receptor modulators, bisphosphonates, RANKL antibody) and anti-diabetic drugs (alpha glucosidase inhibitors, sulfonylureas, biguanides, meglitinides, thiazolidinediones, GLP-1 receptor agonists, dipeptidylpeptidase-4 inhibitors, sodium glucose co-transporter-2 inhibitors, insulin). Biological medications that effectively decrease hyperglycemia and, at the same time, maintain bone health would be an ideal drug/drug combination for the treatment of DM-OS.

AB - Introduction: Currently, 424 million people aged between 20 and 79 years worldwide are diabetic. More than 25% of adults aged over 65 years in North America have Type 2 diabetes mellitus (DM). Diabetes-induced osteoporosis (DM-OS) is caused by chronic hyperglycemia, advanced glycated end products and oxidative stress. The increase in the prevalence of DM-OS has prompted researchers to develop new biological therapies for the management of DM-OS. Areas covered: This review covered the current and novel biological agents used in the management of DM-OS. Data were retrieved from PubMed, Scopus, American Diabetes Association and International Osteoporosis Foundation websites, and ClinicalTrials.gov. The keywords for the search included: DM, osteoporosis, and management. Expert opinion: Several biological molecules have been examined in order to find efficient drugs for the treatment of DM-OS. These biological agents include anti-osteoporosis drugs: net anabolics (parathyroid hormone/analogs, androgens, calcilytics, anti-sclerostin antibody), net anti-resorptive osteoporosis drugs (calcitonin, estrogen, selective estrogen receptor modulators, bisphosphonates, RANKL antibody) and anti-diabetic drugs (alpha glucosidase inhibitors, sulfonylureas, biguanides, meglitinides, thiazolidinediones, GLP-1 receptor agonists, dipeptidylpeptidase-4 inhibitors, sodium glucose co-transporter-2 inhibitors, insulin). Biological medications that effectively decrease hyperglycemia and, at the same time, maintain bone health would be an ideal drug/drug combination for the treatment of DM-OS.

KW - anti-diabetic drugs

KW - anti-osteoporosis drugs

KW - bone

KW - bone mineral density

KW - Diabetes-induced osteoporosis

KW - hormones

UR - http://www.scopus.com/inward/record.url?scp=85066253913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066253913&partnerID=8YFLogxK

U2 - 10.1080/14712598.2019.1618266

DO - 10.1080/14712598.2019.1618266

M3 - Article

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

ER -